Targeting neutrophils in asthma: A therapeutic opportunity?

Biochem Pharmacol. 2020 Dec:182:114292. doi: 10.1016/j.bcp.2020.114292. Epub 2020 Oct 17.

Abstract

Suppression of airway inflammation with inhaled corticosteroids has been the key therapeutic approach for asthma for many years. Identification of inflammatory phenotypes in asthma has moreover led to important breakthroughs, e.g. with specific targeting of the IL-5 pathway as add-on treatment in difficult-to-treat eosinophilic asthma. However, the impact of interfering with the neutrophilic component in asthma is less documented and understood. This review provides an overview of established and recent insights with regard to the role of neutrophils in asthma, focusing on research in humans. We will describe the main drivers of neutrophilic responses in asthma, the heterogeneity in neutrophils and how they could contribute to asthma pathogenesis. Moreover we will describe findings from clinical trials, in which neutrophilic inflammation was targeted. It is clear that neutrophils are important actors in asthma development and play a role in exacerbations. However, more research is required to fully understand how modulation of neutrophil activity could lead to a significant benefit in asthma patients with airway neutrophilia.

Keywords: Asthma; Neutrophilic inflammation.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenal Cortex Hormones / administration & dosage
  • Animals
  • Asthma / drug therapy*
  • Asthma / immunology
  • Asthma / metabolism*
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Humans
  • Inflammation Mediators / antagonists & inhibitors
  • Inflammation Mediators / metabolism*
  • Neutrophils / drug effects*
  • Neutrophils / immunology
  • Neutrophils / metabolism*

Substances

  • Adrenal Cortex Hormones
  • Inflammation Mediators